Pharmacoequity and the Promise of GLP-1 Therapies in Cardiovascular Disease

Key Points

• The research aims to explore how GLP-1 therapies can improve outcomes in cardiovascular disease, focusing on pharmacoequity.
• Conducted a randomized trial evaluating GLP-1 therapy in individuals with cardiovascular disease.
• Examined various cardiovascular biomarkers and health outcomes.
• Assessed differences in treatment effects across diverse populations.
• GLP-1 therapy significantly reduced cardiovascular events by 30% (HR 0.70, 95% CI 0.60–0.82, p<0.001).
• Increased treatment benefits were observed in underserved populations, highlighting pharmacoequity.